Glaukos Corporation (GKOS) Tops Q4 EPS by 5c

Glaukos Corporation (NYSE: GKOS) reported Q4 EPS of ($0.24), $0.05 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $73.2 million versus the consensus estimate of $67.84 million.

“Our solid fourth quarter performance marks the end of an unprecedented year in which our teams displayed an unwavering commitment to advance our key strategic priorities and execute our plans despite the unique challenges associated with the ongoing COVID-19 pandemic,” said Thomas Burns, Glaukos president and chief executive officer. “While we maintain near-term caution as uncertainties associated with COVID-19 persist, I am confident in our execution and the longer-term fundamental prospects of our business remain strong as we advance our mission to transform the treatment of chronic eye diseases for the benefit of patients worldwide.”

For earnings history and earnings-related data on Glaukos Corporation (GKOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15